New PET scan may predict immunotherapy success in lung cancer
NCT ID NCT03564197
First seen Feb 28, 2026 · Last updated May 14, 2026 · Updated 12 times
Summary
This study tested a new type of PET scan that looks for a protein called PD-L1 on cancer cells. The goal was to see if this scan could predict which patients with advanced lung cancer would benefit from the immunotherapy drug nivolumab. Eighty patients received the scan before starting treatment, and researchers tracked their cancer progression over time. The study did not offer a new treatment, but aimed to improve how doctors choose the right therapy for each patient.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC STAGE IV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Antoni van Leeuwenhoek
Amsterdam, 1060CX, Netherlands
-
Antonius Ziekenhuis
Utrecht, Netherlands
-
Deventer Ziekenhuis
Deventer, Netherlands
-
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, Netherlands
-
LUMC
Leiden, Netherlands
-
MeanderMC
Amersfoort, Netherlands
-
Medisch Centrum Haaglanden
The Hague, Netherlands
-
VUmc
Amsterdam, 1007 MB, Netherlands
Conditions
Explore the condition pages connected to this study.